Zymeworks Inc.
ZYMEZymeworks Inc. (ZYME) is a biotechnology company specializing in the development of next-generation multifunctional antibodies for the treatment of cancer and other diseases. Founded in 2008 and headquartered in Vancouver, Canada, Zymeworks utilizes proprietary platform technologies to engineer novel therapeutic candidates, aiming to improve efficacy and safety profiles for targeted therapies.
Company News
Jazz Pharmaceuticals announced positive Phase 3 trial results for Ziihera (zanidatamab-hrii) in treating HER2-positive gastroesophageal adenocarcinoma. The triplet therapy combining Ziihera with tislelizumab and chemotherapy achieved a median overall survival of 26.4 months, the longest reported in a Phase 3 GEA trial, representing a 28% reductio...
Zymeworks announced positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The trial demonstrated statistically significant improvements in progression-free survival (approximately 35% risk red...
Zymeworks Inc. will participate in two upcoming healthcare investor conferences in Miami, including one-on-one meetings and fireside chats, highlighting their biotechnology portfolio and licensed healthcare assets.
Zymeworks, Jazz Pharmaceuticals, and BeOne Medicines reported positive Phase 3 trial results for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma, demonstrating significant improvements in progression-free and overall survival.
Zymeworks, a clinical-stage biotechnology company, announced participation in upcoming investor conferences and highlighted its progress in developing biotherapeutics for cancer and other diseases, including the FDA-approved zanidatamab for biliary tract cancer.
